Rani Therapeutics Holdings, INC Form 4 insider transactions

Michelle Gilson, a Director of Rani Therapeutics Holdings, Inc., received 247,200 shares of common stock on August 3, 2026.

Mir A Imran, a Director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of common stock on July 21, 2026 for $0.69 per share.

Alireza Javadi, Chief Technical Officer of Rani Therapeutics Holdings, Inc., sold 386 shares of common stock on March 27, 2026 for $0.78 per share.

Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., purchased 35,000 shares of common stock on July 17, 2026 for $0.72 per share.

Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., sold 8,014 shares of common stock on December 27, 2024 for $1.41 per share.

Nicholas Maestas, Chief Financial Officer of Rani Therapeutics Holdings, Inc., received 2,000,000 shares of common stock on July 17, 2026.

Chief Business Officer Kate McKinley was granted 805,500 stock options in Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. Chief Technical Officer Alireza Javadi was granted 805,500 stock options.

Rani Therapeutics CEO Imran Talat was granted options to purchase 3.8 million shares of Class A Common Stock.

Rani Therapeutics Holdings, Inc. Director Abraham Bassan acquired stock options for 123,600 shares of Class A Common Stock.

Lisa Ann Rometty, a director at Rani Therapeutics Holdings, Inc., acquired stock options for 123,600 shares.

Rani Therapeutics Holdings, Inc. reports a Form 4 filing detailing the acquisition of stock options by Director Imran Mir.

Jean Luc Butel, a Director at Rani Therapeutics Holdings, Inc., acquired 123,600 stock options with an exercise price of $0.95.

Rani Therapeutics Holdings, Inc. reports that Director Vasudev Jaiprakash Bailey acquired stock options for 123,600 shares.

Dennis A. Ausiello, a Director at Rani Therapeutics Holdings, Inc., acquired 123,600 stock options with an exercise price of $0.95.

Vasudev Jaiprakash Bailey, a director at Rani Therapeutics Holdings, Inc., was granted 100,000 stock options with an exercise price of $2.09, vesting over three years.

Rani Therapeutics Holdings, Inc. Director Abraham Bassan acquired 100,000 stock options with an exercise price of $2.09, signaling potential long-term confidence.

Mir A. Imran, a Director and 10% owner of Rani Therapeutics Holdings, Inc., acquired over 2 million Class A Common Stock shares and warrants in a private placement.

South Cone Investments, a 10% owner and director of Rani Therapeutics Holdings, Inc., reported the sale of 5,923,000 shares of Class A Common Stock over two days.

Rani Therapeutics' Chief Business Officer, Kate McKinley, was granted 120,000 employee stock options at an exercise price of $0.528.

Rani Therapeutics Holdings, Inc. announced that Director Maulik Nanavaty was granted 50,000 stock options with an exercise price of $0.62, vesting over one year or upon specific corporate events.

Rani Therapeutics Holdings, Inc. Director Mir A Imran was granted 50,000 stock options with an exercise price of $0.62, vesting over one year or earlier upon specific corporate events.

Rani Therapeutics Holdings, Inc. Director Lisa Ann Rometty has been granted 50,000 stock options, aligning her interests with shareholder value.

Rani Therapeutics Holdings, Inc. (RANI) disclosed that Director Jean-Luc Butel was granted 50,000 stock options with an exercise price of $0.62 per share.

Dennis A. Ausiello, a Director at Rani Therapeutics Holdings, Inc., was granted 50,000 stock options with an exercise price of $0.62 per share, vesting over one year or upon specific corporate events.

Rani Therapeutics Holdings, Inc. Director Andrew Farquharson was granted 50,000 stock options with an exercise price of $0.62, vesting over one year or earlier upon specific events.

Rani Therapeutics Holdings, Inc. Chief Scientific Officer Mir Hashim was granted 325,000 stock options with an exercise price of $0.6168, vesting over four years.

Rani Therapeutics Holdings, Inc.'s Chief Business Officer, Kate McKinley, was granted 325,000 stock options with an exercise price of $0.6168, vesting monthly over four years.

Rani Therapeutics Holdings, Inc. CEO and Director Talat Imran was granted 1,053,000 stock options with an exercise price of $0.6168, vesting monthly over four years starting May 23, 2025.

Rani Therapeutics Holdings, Inc. Chief Financial Officer, Svai S. Sanford, was granted 325,000 stock options with an exercise price of $0.6168, vesting monthly over four years.